drugset / Trial / NCT05733546
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.
Timeline
- Start
- 2023-01-30
- Primary completion
- 2025-09
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 1 mg | — |
| Subject | Psilocybin | Other / unclassified | 10 mg | — |
| Subject | Psilocybin | Other / unclassified | 25 mg | — |